As a novel therapeutic approach for GJB2-related hearing loss, we recently developed AAV-Sia6e, which is a vector suitable for treating GJB2-related hearing loss with high infectivity of Deiters’ cells, Hensen’s cells, inner and outer sulcus cells, and fibrocytes of the inner ear and reported that this AAV-mediated Gjb2 gene transfer restored the GJIC network and rescued hearing in a Gjb2 conditional knockout mouse model (our unpublished observations). Here, GJB2 is linked to hearing loss disorder.